Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predictors of mortality after prostate-specific antigen failure.

Anthony V D'Amico1, Phillip Kantoff, Marian Loffredo

  • 1Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA. adamico@lroc.harvard.edu

International Journal of Radiation Oncology, Biology, Physics
|May 10, 2006
PubMed
Summary

Advanced age and a short prostate-specific antigen (PSA) doubling time (DT) less than 6 months are linked to shorter survival after PSA failure in men treated with radiation therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality assurance for thyroid FNAs: A more useful way to compare performance.

Cancer cytopathology·2026
Same author

Cytologic diagnosis of papillary renal neoplasm with reverse polarity.

Cancer cytopathology·2024
Same author

Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity.

Journal of the American Society of Cytopathology·2024
Same author

Diagnostic terminology for benign/low-risk tumors on renal cytology.

Cancer cytopathology·2023
Same author

Risk of malignancy in renal biopsy: A review.

Cancer cytopathology·2023
Same author

Low-risk oncocytic renal neoplasm: A useful cytologic diagnosis.

Cancer cytopathology·2023

Area of Science:

  • Urology
  • Oncology
  • Radiation Oncology

Background:

  • Prostate-specific antigen (PSA) failure indicates cancer recurrence after treatment.
  • Understanding factors influencing survival post-PSA failure is crucial for patient management.

Purpose of the Study:

  • To identify predictors of survival duration following PSA failure in men undergoing radiation therapy.
  • To analyze the impact of age and PSA kinetics on outcomes.

Main Methods:

  • Analysis of data from 81 men who experienced PSA failure in a randomized trial of radiation therapy (RT) with or without androgen suppression therapy (AST).
  • Cox regression modeling was employed to assess factors associated with survival length.
  • PSA doubling time (DT) and age at PSA failure were key variables examined.

Related Experiment Videos

Main Results:

  • A PSA DT <6 months and older age at PSA failure were significantly associated with shorter survival (p=0.04 and p=0.009, respectively).
  • Men aged 75+ had higher prostate cancer mortality rates by 5 years post-PSA failure compared to younger men.
  • A PSA DT <6 months predicted a significantly higher likelihood of dying from prostate cancer within 5 years.

Conclusions:

  • Advanced age and a rapid PSA doubling time (<6 months) are significant negative prognostic factors for survival after PSA failure.
  • These findings highlight the importance of PSA kinetics and patient age in predicting outcomes for prostate cancer patients post-treatment.